To analyze the spatiotemporal dynamic evolution of nasopharyngeal carcinoma before and after immunotherapy and during tumor progression, 2\~3 key cell subsets or node molecules were screened to predict the curative effect. Spatial metabolome and organoids were used to elucidate the mechanism of key factors leading to immunotherapy tolerance in NPC and identify new targets for intervention.
Clearly diagnosed with nasopharyngeal carcinoma by pathology;
Patients who have received combined radiotherapy, chemotherapy and immunotherapy in our hospital;
Patients diagnosed in our hospital from January 2025 to December 2028;
Have relatively complete clinical data;
The final diagnosis of the participants is other diseases, including lymphoma, or oropharyngeal cancer, etc.;
The participants failed to obtain pathological and imaging data for various reasons;
Due to physical conditions, they did not undergo relevant examinations, refused to accept examinations, or interrupted treatment for other reasons, and were unable to complete clinical assessment.
Patients with nasopharyngeal carcinoma who were admitted to our hospital
Cohort
Prospective
No Intervention
Other interventionThis project involves no therapeutic intervention for the subjects.
Failure-free survival (FFS)
Failure-free survival is measured from day of diagnosis until treatment failure, death from any cause, or last follow-up visit, whichever occurred first
Overall survival (OS)
Overall survival is measured from day of diagnosis until death due to any cause or the latest known date alive
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
